抗菌药物管理的预先授权与前瞻性审核及反馈的比较。

Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship.

作者信息

Mehta Jimish M, Haynes Kevin, Wileyto E Paul, Gerber Jeffrey S, Timko Daniel R, Morgan Steven C, Binkley Shawn, Fishman Neil O, Lautenbach Ebbing, Zaoutis Theoklis

机构信息

Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

出版信息

Infect Control Hosp Epidemiol. 2014 Sep;35(9):1092-9. doi: 10.1086/677624. Epub 2014 Jul 23.

Abstract

OBJECTIVE

Although prior authorization and prospective audit with feedback are both effective antimicrobial stewardship program (ASP) strategies, the relative impact of these approaches remains unclear. We compared these core ASP strategies at an academic medical center.

DESIGN

Quasi-experimental study.

METHODS

We compared antimicrobial use during the 24 months before and after implementation of an ASP strategy change. The ASP used prior authorization alone during the preintervention period, June 2007 through May 2009. In June 2009, many antimicrobials were unrestricted and prospective audit was implemented for cefepime, piperacillin/tazobactam, and vancomycin, marking the start of the postintervention period, July 2009 through June 2011. All adult inpatients who received more than or equal to 1 dose of an antimicrobial were included. The primary end point was antimicrobial consumption in days of therapy per 1,000 patient-days (DOT/1,000-PD). Secondary end points included length of stay (LOS).

RESULTS

In total, 55,336 patients were included (29,660 preintervention and 25,676 postintervention). During the preintervention period, both total systemic antimicrobial use (-9.75 DOT/1,000-PD per month) and broad-spectrum anti-gram-negative antimicrobial use (-4.00 DOT/1,000-PD) declined. After the introduction of prospective audit with feedback, however, both total antimicrobial use (+9.65 DOT/1,000-PD per month; P < .001) and broad-spectrum anti-gram-negative antimicrobial use (+4.80 DOT/1,000-PD per month; P < .001) increased significantly. Use of cefepime and piperacillin/tazobactam both significantly increased after the intervention (P = .03). Hospital LOS and LOS after first antimicrobial dose also significantly increased after the intervention (P = .016 and .004, respectively).

CONCLUSIONS

Significant increases in antimicrobial consumption and LOS were observed after the change in ASP strategy.

摘要

目的

尽管事先批准和带有反馈的前瞻性审核都是有效的抗菌药物管理计划(ASP)策略,但这些方法的相对影响仍不明确。我们在一家学术医疗中心对这些核心ASP策略进行了比较。

设计

准实验研究。

方法

我们比较了ASP策略改变实施前后24个月内的抗菌药物使用情况。在2007年6月至2009年5月的干预前期,ASP仅采用事先批准。2009年6月,许多抗菌药物不再受限,并对头孢吡肟、哌拉西林/他唑巴坦和万古霉素实施前瞻性审核,这标志着2009年7月至2011年6月干预后期的开始。纳入所有接受了≥1剂抗菌药物的成年住院患者。主要终点是每1000患者日的抗菌药物使用天数(DOT/1000-PD)。次要终点包括住院时间(LOS)。

结果

共纳入55336例患者(干预前期29660例,干预后期25676例)。在干预前期,全身抗菌药物总使用量(每月-9.75 DOT/1000-PD)和广谱抗革兰氏阴性菌抗菌药物使用量(-4.00 DOT/1000-PD)均下降。然而,在引入带有反馈的前瞻性审核后,抗菌药物总使用量(每月+9.65 DOT/1000-PD;P<.001)和广谱抗革兰氏阴性菌抗菌药物使用量(每月+4.80 DOT/1000-PD;P<.001)均显著增加。干预后头孢吡肟和哌拉西林/他唑巴坦的使用量均显著增加(P=.03)。干预后医院住院时间以及首次使用抗菌药物后的住院时间也显著增加(分别为P=.016和.004)。

结论

ASP策略改变后,抗菌药物使用量和住院时间显著增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索